clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Calvet X et al. | Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study. | 2000 | Helicobacter | pmid:10672052 |
Dammann HG et al. | Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. | 2000 | Helicobacter | pmid:10672051 |
Miyabayashi H et al. | Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori. | 2000 | Helicobacter | pmid:10672049 |
Griffith DE et al. | Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. | 2000 | Clin. Infect. Dis. | pmid:10671330 |
Mordi MN et al. | Acid-catalyzed degradation of clarithromycin and erythromycin B: a comparative study using NMR spectroscopy. | 2000 | J. Med. Chem. | pmid:10669574 |
Hoshi T et al. | Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori--a comparison before and after H pylori eradication in non-atrophic gastritis. | 1999 | Hum. Pathol. | pmid:10667417 |
Yatsunami J et al. | Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. | 1999 | Cancer Lett. | pmid:10660084 |
Allevi P et al. | A new convenient transformation of erythromycin A into clarithromycin. | 1999 | Bioorg. Med. Chem. | pmid:10658579 |
Alarcón T et al. | PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. | 2000 | J. Clin. Microbiol. | pmid:10655418 |
Chiba N and Marshall CP | Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. | 2000 | Can. J. Gastroenterol. | pmid:10655024 |
Fock KM et al. | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651664 |
Wong BC et al. | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651663 |
Graham DY et al. | Furazolidone combination therapies for Helicobacter pylori infection in the United States. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651662 |
Miyanohara T et al. | Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. | 2000 | Laryngoscope | pmid:10646728 |
Keiser P et al. | A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection. | 1999 | Int J STD AIDS | pmid:10639059 |
Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
Chan FK et al. | Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632651 |
Gasbarrini A et al. | Efficacy of a multistep strategy for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632649 |
Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
Fujioka T | Clarithromycin resistance in Helicobacter pylori: implications for therapy. | 2000 | J. Gastroenterol. | pmid:10632546 |
Hoshiya S et al. | Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. | 2000 | J. Gastroenterol. | pmid:10632534 |
Juurlink DN and Ito S | Comment: clarithromycin-digoxin interaction. | 1999 | Ann Pharmacother | pmid:10630847 |
Burgess DS et al. | A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. | 1999 | Ann Pharmacother | pmid:10630825 |
Bortolotti M et al. | Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1999 | Dig. Dis. Sci. | pmid:10630494 |
Cammarota G et al. | Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. | 1999 | Dig. Dis. Sci. | pmid:10630486 |
Blondon H | [Eradication of Helicobacter pylori: what is the effect on symptoms of non-ulcerous dyspepsia?]. | 1999 | Presse Med | pmid:10629694 |
Bui KQ et al. | In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. | 2000 | J. Antimicrob. Chemother. | pmid:10629013 |
Lugannani C and Strickland C | Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients? | 1999 | J Fam Pract | pmid:10628582 |
Rocha RT et al. | Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections. | 1999 | Int. J. Clin. Pract. | pmid:10622070 |
Maeda S et al. | Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. | 2000 | J. Clin. Microbiol. | pmid:10618089 |
Gotoda T et al. | Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori. | 1999 | J. Gastroenterol. | pmid:10616774 |
Aoyama N et al. | Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. | 1999 | J. Gastroenterol. | pmid:10616772 |
Kiyota K et al. | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. | 1999 | J. Gastroenterol. | pmid:10616771 |
Abe S et al. | Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. | 2000 | Am. J. Respir. Cell Mol. Biol. | pmid:10615065 |
Midolo PD et al. | In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10614963 |
Giacometti A et al. | In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10614961 |
Suzuki K et al. | Effect of proton pump inhibitor alone or in combination with clarithromycin on mycobacterial growth in human alveolar macrophages. | 2000 | FEMS Microbiol. Lett. | pmid:10612733 |
Ianaro A et al. | Anti-inflammatory activity of macrolide antibiotics. | 2000 | J. Pharmacol. Exp. Ther. | pmid:10604943 |
Ku YY et al. | Synthesis and antibacterial activities of novel 12-O-methylerythromycin A derivatives. | 1999 | J. Antibiot. | pmid:10604761 |
Fernández-Roblas R et al. | In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10602744 |
Hamada K et al. | Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. | 2000 Jan-Feb | Chemotherapy | pmid:10601798 |
Tanaka G et al. | Effect of clarithromycin on Pseudomonas aeruginosa biofilms. | 2000 Jan-Feb | Chemotherapy | pmid:10601796 |
Sainz R et al. | [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. | 1999 | Rev Esp Enferm Dig | pmid:10601771 |
Raderer M et al. | Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. | 2000 | Gut | pmid:10601069 |
Feldman M et al. | Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. | 1999 | Am. J. Physiol. | pmid:10600812 |
Auclair B et al. | Potential interaction between itraconazole and clarithromycin. | 1999 | Pharmacotherapy | pmid:10600094 |
Uygun A et al. | The effect of Helicobacter pylori eradication on duodenal gastric metaplasia. | 1999 Jul-Aug | J. Int. Med. Res. | pmid:10599027 |
Gomollón F et al. | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. | 1999 | Helicobacter | pmid:10597390 |